Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17135166 | 1.00 | EML4 (0.47) | EML4ALKTP53MAPTSMN1; SMN2 | |
| SCHEMBL20374353 | 0.92 | ALDH1A1 (0.49) | EML4ALKTP53MAPTSMN1; SMN2 | |
| SCHEMBL1750144 | 0.85 | EML4 (0.43) | EML4ALKTP53MAPTSMN1; SMN2 | |
| SCHEMBL4259153 | 0.83 | ALDH1A1 (0.48) | MAPTALDH1A1HTTMAP4K4LCK | |
| SCHEMBL22164691 | 0.83 | ALDH1A1 (0.48) | MAPTALDH1A1HTTMAP4K4LCK | |
| SCHEMBL189139 | 0.83 | ALDH1A1 (0.48) | MAPTALDH1A1HTTMAP4K4LCK | |
| SCHEMBL30221466 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1HTTMAP4K4GAA | |
| SCHEMBL15586057 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1HTTMAP4K4GAA | |
| SCHEMBL27959375 | 0.83 | EML4 (0.48) | EML4ALKHSD11B1LCKKDR | |
| SCHEMBL28021938 | 0.83 | EML4 (0.48) | EML4ALKHSD11B1LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | claimed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-9255107-B2 | Heteroaryl alkyne compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-02-09 | — | — | US | disclosed |
| US-20150299202-A1 | HETEROARYL ALKYNE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2927232-A1 | HETEROARYL ALKYNE COMPOUND AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8217045-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | EML4 4560/4885ALK 4002/4885TP53 1069/4885 |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | EML4 4323/4885ALK 39/4885TP53 670/4885 |
| US-20150299202-A1 | HETEROARYL ALKYNE COMPOUND AND USE THEREOF | ABL1, ALK, ABL2 | EML4 2670/4885ALK 2/4885TP53 343/4885 |
| US-20100113467-A1 | Organic Compounds | SLCO2A1, SLCO1B1, SLCO2B1 | EML4 1554/4885ALK 427/4885TP53 686/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | EML4 3988/4885ALK 508/4885TP53 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.